TNF and COVID-19: The current use of inhibitors against TNF‐α for the treatment of COVID‐19 mainly includes monoclonal antibodies, such as adalimumab, golimumab, infliximab, certulizumab, and the TNF‐α receptor fusion protein etanercept.